BMJ Best Practice

参考文献

关键文献

Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291-303.

Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970 Feb;45(239):13-23.

Zacharin M. The spectrum of McCune Albright syndrome. Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:412-8.

Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:752-762.

参考文章

1.  Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291-303.

2.  Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970 Feb;45(239):13-23.

3.  Cesario SK, Hughes LA. Precocious puberty: a comprehensive review of literature. J Obstet Gynecol Neonatal Nurs. 2007;36:263-274.

4.  Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and aetiology. Arch Dis Child. 1994;70:116-118.

5.  Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108:47-54.

6.  Stanhope R, Brook CG, Pringle PJ, et al. Induction of puberty by pulsatile gonadotropin releasing hormone. Lancet. 1987;2:552-555.

7.  Tanner JM. Trend towards earlier menarche in London, Oslo, Copenhagen, the Netherlands and Hungary. Nature. 1973;243:95-96.

8.  Biro FM, Khoury P, Morrison JA. Influence of obesity on timing of puberty. Int J Androl. 2006;29:272-277.

9.  Delemarre-van de Waal HA. Secular trend of timing of puberty. Endocr Dev. 2005;8:1-14.

10.  de la Puente ML, Canela J, Alvarez J, et al. Cross-sectional growth study of the child and adolescent population of Catalonia (Spain). Ann Hum Biol. 1997;24:435-452.

11.  Mul D, Fredriks AM, van Buuren S, et al. Pubertal development in The Netherlands 1965-1997. Pediatr Res. 2001;50:479-486.

12.  Himes JH. Examining the evidence for recent secular changes in the timing of puberty in US children in light of increases in the prevalence of obesity. Mol Cell Endocrinol. 2006;254-255:13-21.

13.  Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008 May 28;299(20):2401-5.

14.  Osler DC, Crawford JD. Examination of the hypothesis of a critical weight at menarche in ambulatory and bedridden mentally retarded girls. Pediatrics. 1973;51:675-679.

15.  Massart F, Parrino R, Seppia P, et al. How do environmental estrogen disruptors induce precocious puberty? Minerva Pediatr. 2006 Jun;58(3):247-54.

16.  Habiby R, Silverman B, Listernick R, et al. Precocious puberty in children with neurofibromatosis type 1. J Pediatr. 1995 Mar;126(3):364-7.

17.  Carmi D, Shohat M, Metzker A, et al. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 1999 Jun;103(6 Pt 1):1257-62.

18.  Teles MG, Bianco SD, Brito VN, et al. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med. 2008 Feb 14;358(7):709-15.

19.  Nanduri VR, Stanhope R. Why is the retention of gonadotropin secretion common in children with panhypopituitarism due to septo-optic dysplasia? Eur J Endocrinol. 1999 Jan;140(1):48-50.

20.  Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003 Oct;24(5):668-93.

21.  Proos LA, Hofvander Y, Tuvemo T. Menarcheal age and growth pattern of Indian girls adopted in Sweden - I: menarcheal age. Acta Paediatr Scand. 1991 Aug-Sep;80(8-9):852-8.

22.  Herman-Giddens ME, Sandler AD, Friedman NE. Sexual precocity in girls: an association with sexual abuse? Am J Dis Child. 1988 Apr;142(4):431-3.

23.  Nogueira K, Liberman B, Pimentel-Filho FR, et al. hCG-secreting pineal teratoma causing precocious puberty: report of two patients and review of the literature. J Pediatr Endocrinol Metab. 2002 Sep-Oct;15(8):1195-201.

24.  Ojeda SR, Lomniczi A, Mastronardi C, et al. Minireview: the neuroendocrine regulation of puberty: is the time ripe for a systems biology approach? Endocrinology. 2006;147:1166-1174.

25.  Martha PM Jr, Rogol AD, Veldhuis JD, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab. 1989;69:563-570.

26.  Veldhuis JD, Metzger DL, Martha PM Jr, et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab. 1997;82:3414-3420.

27.  Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab. 1994 Jun;78(6):1282-6.

28.  Zacharin M. The spectrum of McCune Albright syndrome. Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:412-8.

29.  Volkl TM, Dorr HG. McCune-Albright syndrome: clinical picture and natural history in children and adolescents. J Pediatr Endocrinol Metab. 2006 May;19 Suppl 2:551-9.

30.  Mieszczak J, Eugster EA. Treatment of precocious puberty in McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:419-22.

31.  Latronico AC, Abell AN, Arnhold IJ, et al. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab. 1998 Jul;83(7):2435-40.

32.  Kremer H, Martens JW, van Reen M, et al. A limited repertoire of mutations of the luteinizing hormone (LH) receptor gene in familial and sporadic patients with male LH-independent precocious puberty. J Clin Endocrinol Metab. 1999 Mar;84(3):1136-40.

33.  Jung H, Parent AS, Ojeda SR. Hypothalamic hamartoma: a paradigm/model for studying the onset of puberty. Endocr Dev. 2005;8:81-93.

34.  Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952 Apr;40(4):423-41.

35.  Mahachoklertwattana P, Kaplan SL, Grumbach MM. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history. J Clin Endocrinol Metab. 1993 Jul;77(1):118-24.

36.  Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007 May;92(5):1697-704.

37.  Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005 Dec;116(6):e798-802.

38.  Tuvemo T. Treatment of central precocious puberty. Expert Opin Investig Drugs. 2006 May;15(5):495-505.

39.  Galluzzi F, Salti R, Bindi G, et al. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr. 1998 May;87(5):521-7.

40.  Paul D, Conte FA, Grumbach MM, et al. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab. 1995 Feb;80(2):546-51.

41.  Kletter GB, Kelch RP. Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. 1994 Aug;79(2):331-4.

42.  Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:752-762.

43.  Carel JC, Lahlou N, Roger M, et al. Precocious puberty and statural growth. Hum Reprod Update. 2004 Mar-Apr;10(2):135-47.

44.  Saggese G, Bertelloni S, Baroncelli GI, et al. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr. 1993 Sep;152(9):717-20.

45.  Kauli R, Galatzer A, Kornreich L, et al. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue: a comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res. 1997;47(2):54-61.

46.  Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab. 1999 Jan-Feb;12(1):81-3.

47.  Almeida MQ, Brito VN, Lins TS, et al. Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clin Endocrinol (Oxf). 2008 Jul;69(1):93-8.

48.  Laron Z, Kauli R. Experience with cyproterone acetate in the treatment of precocious puberty. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:805-10.

49.  Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med. 1986 Oct 30;315(18):1115-9.

50.  Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab. 2007 Jun;92(6):2100-6.

51.  Kreher NC, Pescovitz OH, Delameter P, et al. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr. 2006 Sep;149(3):416-20.

52.  Feuillan P, Merke D, Leschek EW, et al. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer. 1999 Jun;6(2):303-6.

53.  Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab. 1999 Jan;84(1):175-8.

54.  Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989 Feb 23;320(8):496-502.

55.  Medicines and Healthcare Products Regulatory Agency. Press release: Oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013. http://www.mhra.gov.uk/ [internet publication].

56.  European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013. http://www.ema.europa.eu/ema/ [internet publication].

57.  Lee PA. Medroxyprogesterone therapy for sexual precocity in girls. Am J Dis Child. 1981 May;135(5):443-5.

58.  Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003 Jul;143(1):60-6.

59.  Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009 Sep-Oct;15(suppl 2):1-29.

60.  GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3.

61.  Paterson WF, McNeill E, Young D, et al. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf). 2004;61:626-634.

62.  Paterson WF, Hollman AS, Reid S, et al. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Arch Dis Child. 1998;79:323-327.

使用此内容应接受我们的免责声明